MPT0E028 |
| Catalog No.GC65965 |
MPT0E028은 HDAC1, HDAC2 및 HDAC6에 대해 IC50이 각각 53.0nM, 106.2nM, 29.5nM인 경구 활성 선택적 HDAC 억제제입니다. 821d96072c2d58d8970e76f526b0f6b8MPT0E028은 세포사멸을 유도하여 B세포 림프종의 생존력을 감소시키고 강력한 직접 Akt 표적화 능력을 보유하며 B세포 림프종에서 Akt 인산화를 감소시킵니다. 821d96072c2d58d8970e76f526b0f6b8MPT0E028은 우수한 항암 활동을 합니다.821d96072c2d58d8970e76f526b0f6b8
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1338320-94-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MPT0E028 is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively[1]. MPT0E028 reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. MPT0E028 has good anticancer activity[2].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *